The Massachusetts Medicaid analysis published in Nature Medicine represents the largest real-world evaluation to date of medically tailored meals (MTM), showing 31% fewer hospitalizations and 20% fewer emergency visits among 1,866 participants versus matched controls, with net savings for conditions like heart disease and diabetes. As an observational study using claims data from 2020-2023 across 11 systems, it lacks randomization, leaving room for residual confounding despite extensive matching on demographics, comorbidities, and prior utilization; this contrasts with smaller randomized trials of MTM that have shown similar but more modest effect sizes. The rapid onset of benefits within months, sustained over up to 33 months of delivery by Community Servings, points to nutrition's direct role in stabilizing chronic disease, yet the study overlooks potential equity gaps in food-insecure populations and does not quantify adherence or dietary quality metrics. Linking this to broader healthcare economics, MTM aligns with value-based models by reducing high-cost acute care—echoing patterns in CMS pilots across a dozen states—while avoiding cuts to essential primary care visits. Related evidence from a 2023 Health Affairs observational analysis of produce prescription programs (n>4,000) demonstrates parallel 15-25% drops in HbA1c and utilization, reinforcing food-as-medicine scalability, though both share conflicts of interest through nutrition institute funding. A 2022 JAMA Network Open RCT on home-delivered meals for heart failure patients further supports cost offsets but highlights smaller samples and short durations as limitations. These findings position MTM as a bridge from pilot to policy, potentially bending cost curves in Medicaid's $600B+ annual spend, provided future RCTs address causality and long-term outcomes.